NCT04529629 Precise Diagnosis, Treatment and Prognostic Evaluation of Complicated Adrenal Tumor Diseases
| NCT ID | NCT04529629 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Jiao Tong University School of Medicine |
| Condition | Complicated Adrenal Tumor Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2021-08-30 |
| Primary Completion | 2040-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2021-08-30 with a primary completion date of 2040-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The adrenal gland is an important organ that produces life hormones. There are many types of adrenal tumors, which tend to occur in young adults and affect the whole body. It has the dual threat: hormone secretion and tumor metastasis. At present, there are four major dilemmas in the clinical diagnosis and treatment of adrenal tumors: 1) Pulse secretion of the hormones, which are affected by many factors; and the diagnostic value of single hormone is limited; 2) Traditional imaging cannot accurately reflect the characteristics of hormone secretion. The prognosis cannot be accurately predicted; 3) The molecular characteristics of tumor cells and the microenvironment are unclear, making it difficult to implement early diagnosis and precise treatment; 4) Traditional pathology cannot determine the nature and long-term prognosis of the tumor, which makes the treatment delay, and the disease prognosis is extremely poor. It threatens the lives of patients. Starting from solving the above-mentioned key problems in the early stage, the research team has systematically established new clinical diagnostic technologies, hormone dynamic tests to accurately assess hormone secretion and segmented blood collection hormone determination technologies to accurately locate adrenal tumors; A series of important research results have been published in Science, Lancet Diabetes \& Endocrinology, Cell Research, etc To sum up, the goal of this research is improving the early diagnosis rate of complicated adrenal tumors especially in malignant tumors, developing the optimal treatment plan, avoiding unnecessary surgical treatment, improving the quality of life of patients, reducing mortality. This project will further integrate the adrenal cortex and medulla hormone mass spectrometry detection and the molecular markers of adrenal tumors through phenotypic, functional imaging, and molecular pathological evaluations, and built a sensitive drug screening platform that integrates visual drug response and molecular characteristics, thereby achieving precise diagnosis and treatment of complicated adrenal tumors.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old and ≤ 75 years * Diagnosis of Patients with primary aldosteronism, pheochromocytoma, and cortical cancer * Gender: males and females * Provide written informed consent * Satisfactory compliance Exclusion Criteria: 1. Patients with renal insufficiency (Cr\>2 times the upper limit of normal). 2. Patients with a history of liver cirrhosis. 3. Patients who are currently using corticosteroids. 4. Patients with cardiac insufficiency (NYHA cardiac function classification grade 3 and above or EF\<50%). 5. Patients with stroke and acute myocardial infarction in the past 6 months. 6. Patients during pregnancy and lactation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04529629 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Complicated Adrenal Tumor Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04529629 currently recruiting?
Yes, NCT04529629 is actively recruiting participants. Contact the research team at rainy0409@hotmail.com for enrollment information.
Where is the NCT04529629 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT04529629 clinical trial?
NCT04529629 is sponsored by Shanghai Jiao Tong University School of Medicine. The trial plans to enroll 1,000 participants.